Home
Search
SurgiMabSurgiMab
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
In the press : “SurgiMab to sign a deal with a French CMO…”
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
EnglishEnglishFrançaisFrançais

In the press : “SurgiMab to sign a deal with a French CMO…”

SurgiMab > News & Events > News > In the press : “SurgiMab to sign a deal with a French CMO…”
5 June 2012 Administrateur SurgiMabLeave a comment0

On the occasion of the Grenoble EuroMedtech meeting that took place between May 31st and June 1st 2012, Françoise Cailler, SurgiMab’s president, answered BioPharmInsight‘s questions (the Financial Times group). She describes the next steps for SurgiMab in terms of development.

Read the article: SurgiMAB to sign a deal with French CMO…

Previous Post
SurgiMab is awarded the “Innovative Enterprise” certification from Oseo
Next Post
8th annual meeting of the European Society for Molecular Imaging – ESMI

Recent Posts

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
  • SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.
  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
SurgiMab
Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
Home . Legal & credits
Copyright © 2023 SurgiMab. Website by B-to-B Design